Skip to content
Study details
Enrolling now

Nicotinic Receptor Genetic Variation and Alcohol Reward

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NCT IDNCT03294460ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

128

Study length

about 6.6 years

Ages

21–60

Locations

1 site in MD

About this study

Researchers are testing how different people react to alcohol, especially those with a nicotine receptor gene that may increase their risk of alcohol use disorder. The trial will involve healthy adults who are smokers or non-smokers, and it will investigate how variations in this gene affect brain responses to alcohol cues.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive Alcohol (IV)
  • 2.Take Alcohol (Ethanol)
  • 3.Take Alcohol (Oral)
PhasePhase 1
DrugAlcohol (Ethanol)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

ethanol, DERMATOLOGICALS

Drug routes

infusion, oral